Natriuretic polypeptides

Patent metadata

Field	Value
Publication number	US-10344068-B2
Application number	US-201715411630-A
Country	US
Kind code	B2
Filing date	Jan 20, 2017
Priority date	Aug 30, 2011
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.

First claim

What is claimed is:

1. A chimeric polypeptide comprising, in an order from amino terminus to carboxy terminus:
(a) the sequence set forth in SEQ ID NO:1 or the sequence set forth in SEQ ID NO:1 with two or less additions, deletions, or substitutions,
(b) the sequence set forth in SEQ ID NO:7, the sequence set forth in SEQ ID NO:7 with no more than two additions, deletions, or substitutions, the sequence set forth in SEQ ID NO:9, or the sequence set forth in SEQ ID NO:9 with no more than two additions, deletions, or substitutions, and
(c) the sequence set forth in SEQ ID NO:30 or the sequence set forth in SEQ ID NO:30 with no more than two additions, deletions, or substitutions.

2. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1.

3. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1 with one addition, deletion, or substitution.

4. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1 with two additions, deletions, or substitutions.

5. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:7.

6. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:7 with one addition, deletion, or substitution.

7. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:7 with two additions, deletions, or substitutions.

8. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:9.

9. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:9 with one addition, deletion, or substitution.

10. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:9 with two additions, deletions, or substitutions.

11. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:30.

12. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:30 with one addition, deletion, or substitution.

13. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:30 with two additions, deletions, or substitutions.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Lee Candace Y W
• Burnett Jr John C

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07K14/58 Primary

  Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin · CPC title

• A61P13/12

  of the kidneys · CPC title